Corcept Therapeutics
CORT · Nasdaq · United States
Share price · CORT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CORT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Oct 2026-20.1%
Nothing announced by CORT that day or the session before.
- 30 Jul 2026+27.3%
- 27 May 2026+10.4%
- 13 May 2026+11.6%
Nothing announced by CORT that day or the session before.
- 1 May 2026+10.5%
- 25 Mar 2026+19.7%
- 31 Dec 2025-50.4%
- 30 Dec 2025-12.1%
Nothing announced by CORT that day or the session before.
- 16 Dec 2025-7.1%
Nothing announced by CORT that day or the session before.
Share of unusual movement by asset
For each asset, the share of CORT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
mifepristone(Korlym) | Approved | Progesterone receptor; Glucocorticoid receptorSmall molecule | Cushing's Syndrome |
| Approved | Glucocorticoid receptorSmall molecule | Cushing's SyndromeOvarian Cancer | |
| Phase 2 | Glucocorticoid receptorSmall molecule | Amyotrophic Lateral Sclerosis | |
| Phase 2 | Glucocorticoid receptorSmall molecule | MASH / NASH |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (2)
September 2027 (1)
What to watch
December 2027 (1)
What to watch
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $340M | $57M | $99M+ $272M short-term inv. | —$143M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $256M | $54M | $112M+ $197M short-term inv. | —$34M operating cash flow | report ↗ |
| 2026-Q1 | $165M | $66M | $110M+ $229M short-term inv. | $32M-$17M operating cash flow | report ↗ |
| 2025-Q3 | $208M | $69M | $125M+ $297M short-term inv. | —$54M operating cash flow | report ↗ |
| 2025-Q2 | $194M | $60M | $103M+ $239M short-term inv. | —$44M operating cash flow | report ↗ |
| 2025-Q1 | $157M | $61M | $90M+ $233M short-term inv. | —$5.1M operating cash flow | report ↗ |
| 2024-Q3 | $183M | $59M | $137M+ $243M short-term inv. | —$74M operating cash flow | report ↗ |
| 2024-Q2 | $164M | $59M | $129M+ $345M short-term inv. | —$41M operating cash flow | report ↗ |
| 2024-Q1 | $147M | $59M | $150M+ $261M short-term inv. | —$24M operating cash flow | report ↗ |
| 2023-Q3 | $124M | $46M | $112M+ $243M short-term inv. | —$53M operating cash flow | report ↗ |
| 2023-Q2 | $118M | $43M | $172M+ $191M short-term inv. | —$42M operating cash flow | report ↗ |
| 2023-Q1 | $106M | $41M | $300M+ $165M short-term inv. | —$26M operating cash flow | report ↗ |
| 2022-Q3 | $102M | $33M | $50M+ $346M short-term inv. | —$34M operating cash flow | report ↗ |
| 2022-Q2 | $103M | $33M | $35M+ $335M short-term inv. | —$18M operating cash flow | report ↗ |
| 2022-Q1 | $94M | $28M | $62M+ $284M short-term inv. | —$35M operating cash flow | report ↗ |
| 2021-Q3 | $96M | $28M | $95M+ $267M short-term inv. | —$49M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $761M | $255M | $121M+ $252M short-term inv. | —$142M operating cash flow | report ↗ |
Corcept reported full-year 2025 revenue of $761.4M, up 12.8% YoY, and R&D spend of $254.9M, up 3.2% YoY. Cash and investments were $532.4M at December 31, 2025, and net income was $99.7M, or $0.82 diluted EPS. The company guided full-year 2026 revenue to $900 million to $1,000 million. It is engaged with the FDA on relacorilant in Cushing’s syndrome after a Complete Response Letter, while its NDA for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer has a July 11, 2026 PDUFA date and the related MAA is under EMA review. ROSELLA met both dual primary endpoints with a 35% reduction in risk of death, MOMENTUM results are scheduled for an ACC presentation in March, BELLA and MONARCH results are expected by the end of 2026, and a Phase 3 dazucorilant trial in ALS is planned to begin mid-2026. Corcept also paid $245.9M for common stock purchases, net option exercises and restricted stock vesting, and completed its specialty pharmacy transition.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $675M | $247M | $128M+ $256M short-term inv. | —$198M operating cash flow | report ↗ |
| 2023-FY | $482M | $184M | $136M+ $233M short-term inv. | —$127M operating cash flow | report ↗ |
| 2022-FY | $402M | $131M | $66M+ $365M short-term inv. | —$120M operating cash flow | report ↗ |
| 2021-FY | $366M | $114M | $78M+ $146M short-term inv. | —$168M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($3.3M), 112 sales ($98.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | WILSON JAMES N · director | Open-market sale | 2,191 | $71.80 | $157K | Form 4 |
| 2026-11-13 | WILSON JAMES N · director | Open-market sale | 7,221 | $72.87 | $526K | Form 4 |
| 2026-11-13 | WILSON JAMES N · director | Open-market sale | 563 | $73.42 | $41K | Form 4 |
| 2026-11-13 | WILSON JAMES N · director | Open-market sale | 25 | $74.28 | $2K | Form 4 |
| 2026-11-10 | Swisher Daniel N JR · director | Option exercise | 1,100 | $14.08 | $15K | Form 4 |
| 2026-11-10 | Swisher Daniel N JR · director | Option exercise | 400 | $10.50 | $4K | Form 4 |
| 2026-11-10 | Swisher Daniel N JR · director | Open-market sale | 1,500 | $74.07 | $111K | Form 4 |
| 2026-11-10 | Swisher Daniel N JR · director | Option exercise (derivative) | 1,100 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 348 reporting institutions held 79.2M shares ($2.8B, 72.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 12,151,276 | $489.8M |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 5,682,783 | $229.1M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,820,568 | $194.3M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4,077,196 | $164.4M |
| 5 | Parallel Advisors, LLC | 3,977,404 | $160.3M |
| 6 | STATE STREET CORP | 3,200,946 | $129.0M |
| 7 | FMR LLC | 3,190,192 | $128.6M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2,713,519 | $109.4M |
| 9 | FIRST TRUST ADVISORS LP | 2,173,376 | $87.6M |
| 10 | DIMENSIONAL FUND ADVISORS LP | 1,553,135 | $62.6M |
| 11 | TANG CAPITAL MANAGEMENT LLC | 1,500,000 | $60.5M |
| 12 | UBS Group AG | 1,363,668 | $55.0M |
| 13 | D. E. Shaw & Co., Inc. | 1,181,348 | $47.6M |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,119,959 | $45.1M |
| 15 | MORGAN STANLEY | 1,018,845 | $41.1M |